{"id":"NCT03226522","sponsor":"Axsome Therapeutics, Inc.","briefTitle":"Addressing Dementia Via Agitation-Centered Evaluation","officialTitle":"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-07-13","primaryCompletion":"2020-04-17","completion":"2020-04-17","firstPosted":"2017-07-21","resultsPosted":"2023-09-13","lastUpdate":"2023-09-13"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Agitation in Patients With Dementia of the Alzheimer's Type","Alzheimer Disease","Agitation,Psychomotor"],"interventions":[{"type":"DRUG","name":"AXS-05","otherNames":[]},{"type":"DRUG","name":"Bupropion","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AXS-05","type":"EXPERIMENTAL"},{"label":"Bupropion","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.","primaryOutcome":{"measure":"Change in CMAI Total Score","timeFrame":"5 weeks","effectByArm":[{"arm":"AXS-05","deltaMin":-15.4,"sd":1.25},{"arm":"Bupropion","deltaMin":-10,"sd":3.02},{"arm":"Placebo","deltaMin":-11.5,"sd":1.1}],"pValues":[{"comp":"OG000 vs OG002","p":"0.010"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":78,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":["http://www.axsome.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":159},"commonTop":["Dizziness","Somnolence","Diarrhea","Fall","Headache"]}}